Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta

Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck Department of Neurology, Technische Universität München, Munich, Germany Abstract: Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Castrop F, Haslinger B, Hemmer B, Buck D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a102b9304f3a4140a948739e850e1b16
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a102b9304f3a4140a948739e850e1b16
record_format	dspace
spelling	oai:doaj.org-article:a102b9304f3a4140a948739e850e1b162021-12-02T04:01:44ZReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta1176-63281178-2021https://doaj.org/article/a102b9304f3a4140a948739e850e1b162013-09-01T00:00:00Zhttp://www.dovepress.com/review-of-the-pharmacoeconomics-of-early-treatment-of-multiple-scleros-a14369https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck Department of Neurology, Technische Universität München, Munich, Germany Abstract: Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta. Keywords: MS, pharmacoeconomics, disease-modifying therapy, interferon beta, CISCastrop FHaslinger BHemmer BBuck DDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1339-1349 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Castrop F Haslinger B Hemmer B Buck D Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
description	Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck Department of Neurology, Technische Universität München, Munich, Germany Abstract: Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta. Keywords: MS, pharmacoeconomics, disease-modifying therapy, interferon beta, CIS
format	article
author	Castrop F Haslinger B Hemmer B Buck D
author_facet	Castrop F Haslinger B Hemmer B Buck D
author_sort	Castrop F
title	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
title_short	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
title_full	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
title_fullStr	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
title_full_unstemmed	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
title_sort	review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/a102b9304f3a4140a948739e850e1b16
work_keys_str_mv	AT castropf reviewofthepharmacoeconomicsofearlytreatmentofmultiplesclerosisusinginterferonbeta AT haslingerb reviewofthepharmacoeconomicsofearlytreatmentofmultiplesclerosisusinginterferonbeta AT hemmerb reviewofthepharmacoeconomicsofearlytreatmentofmultiplesclerosisusinginterferonbeta AT buckd reviewofthepharmacoeconomicsofearlytreatmentofmultiplesclerosisusinginterferonbeta
_version_	1718401509336547328

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta

Ejemplares similares